About Us

About Molecular Detection (MDI)

Molecular Detection Inc. (MDI) is developing and commercializing a portfolio of "sample-to-answer" Detect-Ready™ molecular diagnostic tests for the rapid detection of infectious diseases. MDI's first Detect-Ready™ assay is a ready-to-use, "sample-to-answer" rapid detection screening test for the growing problem of MRSA (methicillin-resistant S. aureus) infection, a costly and potentially deadly pathogen increasingly found in hospitals and other health facilities.

MDI’s mission is to become a leading molecular diagnostics company leveraging its novel technologies to commercialize products for the accurate, rapid and cost-effective detection of infectious diseases. MDI's Detect-Ready MRSA assay is a real-time PCR test designed to provide increased accuracy, faster time to results and more efficient utilization of hospital resources than other MRSA diagnostic products. MDI is also developing Detect-Ready assays to test for the presence of other microbial agents, including C.difficile, sexually transmitted diseases (STDs) and foodborne pathogens. The company’s products are based on novel patent-pending technologies that provide greater accuracy and speed while simplifying assay storage and use.

MDI was founded in 2007 and is headquartered in Wayne, PA. It has research operations and an ISO 9001 and 13485

Intellectual Property

MDI has the rights to an extensive portfolio of patent applications around its Detect-Ready™ molecular diagnostic testing platform for infectious disease detection. The patent applications define a differential diagnosis engine that can identify MRSA or other specific pathogens of interest in clinical samples while also differentiating them from other infectious sources. The patents cover methods for MRSA detection and methods for differential diagnosis of antibiotic resistant strains and non-resistant strains for a wide range of infections.

MDI also owns the rights to patent applications that cover the unique features of its technology platform